Primary Site >> Pancreatic Cancer
Gene >> HDAC9
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
|
Ref: Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. PMID: 17417771 |
Ref: Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitors-nanomolar-potency inhibitors of pancreatic cancer cell growth. PMID: 18181121 Ref: Synthesis and biological evaluation of histone deacetylase inhibitors that are based on FR235222: a cyclic tetrapeptide scaffold. PMID: 18381239 Ref: Array-based approaches for the identification of epigenetic silenced tumor suppressor genes. PMID: 19424480 |
Ref: Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells. PMID: 20484017 |
Ref: Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-alpha on pancreatic cancer cells. PMID: 21556798 Ref: Effective neurofibromatosis therapeutics blocking the oncogenic kinase PAK1. PMID: 22466437 |
Ref: Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. PMID: 22080430 Ref: A ZEB1-HDAC pathway enters the epithelial to mesenchymal transition world in pancreatic cancer. PMID: 22147511 Ref: Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. PMID: 22147512 |
Ref: (-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity. PMID: 23135610 |
Ref: TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis. PMID: 25762644 Ref: Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595. PMID: 26084607 Ref: Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells. PMID: 26349994 |
Ref: SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin. PMID: 26493999 Ref: Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes. PMID: 26586478 Ref: Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. PMID: 27197284 |
Ref: A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis. PMID: 28107195 |
Ref: Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer. PMID: 29995287 |